A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
- Status
- UNKNOWN
- Phase
- NA
Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
ICI 182780 in Treating Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
- Status
- UNKNOWN
- Phase
- PHASE2